Dengue Hemorrhagic Fever Clinical Trial
— PKIDENOfficial title:
Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients
Verified date | February 2021 |
Source | Mahidol University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Design and Outcomes This research study is designed as open-label, sequential dose-escalating clinical trial. There will be two phases of enrollment. In the first phase, pediatric dengue patients with body weight greater than 30 kg will be recruited. The first six volunteers will be administered with 400 μg/kg every 24 hours for a total of three times. The last six volunteers will be administered with 600 μg/kg every 24 hours for a total of three times. In the second phase, pediatric dengue patients with body weight between 15 to 30 kg will be recruited. Similar to the first phase, the first six and the last six volunteers will be administered with 400 μg/kg and 600 μg/kg every 24 hours for a total of three times, respectively. A total of 24 volunteers will be recruited from Faculty of Medicine Siriraj hospitals
Status | Completed |
Enrollment | 24 |
Est. completion date | September 22, 2020 |
Est. primary completion date | September 22, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 15 Years |
Eligibility | Inclusion Criteria: 1. Aged between 1-15 years 0 day 2. Weight is equal or greater than 15 kg 3. History or presence of acute fever within the last 72 hours diagnosed as acute dengue virus infection 4. Patients who are expected to be able to start the study drug within 72 hours of fever 5. Written informed consent to enroll in the study is obtained from parents or legal representatives and/or patients. 6. The test for dengue nonstructural protein 1 is positive, or PCR screening for viral genome is positive 7. Female patients with history of menarche need to have a negative result for urine pregnancy test, except during a menstrual period. Exclusion Criteria: 1. Has significant underlying disease(s) that can affect the study outcome or the study participation may be harmful to patients with those underlying diseases including but not limited to: - Kidney disease - Thalassemia - congenital heart disease - epilepsy - cerebral palsy Other underlying diseases may result in exclusion depending on the judgement of investigator. 2. Having developed or showed the following laboratory values, warning signs or signs of severe dengue including: - AST and/or ALT levels > 500 IU/L - Platelets count < 50,000 cells/mm3 - Abdominal pain or tenderness - Persistent vomiting - Clinical fluid accumulation such as pleural effusion, ascites - Mucosal bleeding - Lethargy/restlessness - Liver enlargement >2 cm - Increase in Hct concurrent with rapid decrease in platelet count - Severe plasma leakage such as dengue shock syndrome, fluid accumulation with respiratory distress - Severe bleeding as evaluated by clinician - Severe organ involvement including but not limited to acute liver failure, altered level of consciousness (e.g. encephalopathy, encephalitis), seizure or other CNS unusual manifestation, acute renal failure, cardiomyopathy and other unusual manifestation 3. History of ivermectin allergy or receiving medications that increase gamma-aminobutyric acid (GABA) potentiating activity such as barbiturates, benzodiazepines, sodium oxybate, valproic acid, or receiving medications that prevent p-glycoprotein transport system such as amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil, amprenavir, clotrimazole, phenothiazines, rifampin, St. John's Wort etc. 4. Currently receiving immunosuppressive agents such as steroid (except topical steroid), chemotherapeutic agents or have discontinued these medications for less than a month 5. Having a history of receiving ivermectin within one month 6. Inability to ingest medications in a form of tablets as informed by patients and their parents or legal representatives |
Country | Name | City | State |
---|---|---|---|
Thailand | Faculty of Tropical Medicine Siriraj Hospital | Bangkok Noi | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Mahidol University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pharmacokinetics of ivermectin in pediatric dengue patients | Blood samples will be collected, and ivermectin plasma concentrations will be measured with High Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS). | 7 days | |
Secondary | Pharmacodynamic effects of ivermectin on viral load in plasma of pediatric dengue patients | Blood samples will be collected, and viral load in plasma will be measured with quantitative RT-PCR. | 7 days | |
Secondary | Pharmacodynamic effects of ivermectin on NS1 antigen in plasma of pediatric dengue patients | Blood samples will be collected, and NS1 antigen in plasma will be measured with NS1-ELISA assay. | 7 days | |
Secondary | Viremia clearance | Time between the first drug administration and the point of specimen collection at which viral load becomes undetectable | 7 days | |
Secondary | NS1 antigenemia clearance | Time between the first drug administration and the point of specimen collection at which NS1 antigen becomes undetectable | 7 days | |
Secondary | Occurrences of adverse events | The number of volunteers with any adverse events by the total number of volunteers in the treatment group | 7 days | |
Secondary | Occurrences of abnormal laboratory result | The number of volunteers with any change of laboratory results from normal at baseline to abnormal during the study by the total number of volunteers in the treatment group. | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT00788151 -
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
|
Phase 2 | |
Completed |
NCT01477671 -
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
|
N/A | |
Completed |
NCT01983553 -
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
|
||
Completed |
NCT01134263 -
Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
|
Phase 3 | |
Completed |
NCT02741128 -
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
|
Phase 2 | |
Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
Completed |
NCT01943825 -
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
|
Phase 2 | |
Completed |
NCT02979535 -
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
|
Phase 3 | |
Completed |
NCT02628444 -
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
|
Phase 2 | |
Completed |
NCT01550289 -
Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
|
Phase 2 | |
Completed |
NCT00875524 -
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
|
Phase 2 | |
Completed |
NCT00458120 -
Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus
|
Phase 1 | |
Completed |
NCT01374516 -
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
|
Phase 3 | |
Completed |
NCT01373281 -
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
|
Phase 3 | |
Completed |
NCT04048837 -
Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore
|
||
Completed |
NCT00919178 -
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
|
Phase 1 | |
Completed |
NCT00468858 -
A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children
|
Phase 2 | |
Completed |
NCT01411241 -
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT02824198 -
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
|
Phase 2 |